SCHEMBL6407420

SCHEMBL6407420

CCCCOc1ccc(C(=N)NO)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 2/20 0.56
CYP1A2 P05177 2/20 0.53
KDM4E B2RXH2 1/20 0.53
CYP2D6 P10635 1/20 0.53
PDE4A P27815 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HIF1A Q16665 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
GAA P10253 1/20 0.51
RAB9A P51151 1/20 0.51
TP53 P04637 1/20 0.51
TSHR P16473 1/20 0.51
PRSS1 P07477 1/20 0.50
PLA2G4B P0C869 1/20 0.50
TMPRSS2 O15393 1/20 0.50
CYP19A1 P11511 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8718224 0.97 TP53 (0.57) MMP1GAARAB9ATP53TSHR
SCHEMBL15020066 0.95 TP53 (0.59) CYP2D6GAARAB9ATP53TSHR
SCHEMBL7341007 0.95 TP53 (0.59) CYP2D6GAARAB9ATP53TSHR
SCHEMBL6510086 0.95 TP53 (0.59) CYP2D6GAARAB9ATP53TSHR
SCHEMBL3275310 0.93 PLK1 (0.56) MMP1CYP1A2KDM4ECYP2D6PDE4A
SCHEMBL548439 0.91 PRSS1 (0.60) CYP2D6GAAPRSS1TMPRSS2
SCHEMBL549185 0.91 TMPRSS2 (0.60) MMP1CYP2D6PRSS1TMPRSS2
Pentamidine Dao SCHEMBL548448 0.89 PRMT1 (0.61) CYP2D6GAAPRSS1TMPRSS2
Maleic Acid SCHEMBL6407424 0.88 MMP1 (0.53) MMP1CYP1A2KDM4ECYP2D6PDE4A
SCHEMBL23588050 0.86 TMPRSS2 (0.51) MMP1CYP2D6PRSS1TMPRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0861071-B1 BENZAMIDOXIME PRODRUGS AND USE THEREOF FOR TREATING PNEUMONIA UNIV NORTH CAROLINA (US) 2005-05-11 EP claimed
WO-2024089421-A1 TETRAZOLE DERIVATIVES SITRYX THERAPEUTICS LIMITED (GB) 2024-05-02 WO disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 CN disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 WO disclosed
EP-1561463-A2 Benzamidoxime prodrugs as antipneumocystic agents THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2005-08-10 EP disclosed
EP-0861071-B1 BENZAMIDOXIME PRODRUGS AND USE THEREOF FOR TREATING PNEUMONIA UNIV NORTH CAROLINA (US) 2005-05-11 EP disclosed
US-6423737-B2 Benzamidoxime prodrugs as antipneumocystic agents THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2002-07-23 US disclosed
US-20010044468-A1 Benzamidoxime prodrugs as antipneumocystic agents HALL JAMES E (US) 2001-11-22 US disclosed
US-6214883-B1 BIS//N-HYDROXYAMIDINO/PHENOXY OR -THIO/ALKANES REDUCED AFTER ORAL ADMINISTRATION TO THE CORRESPONDING MONO- OR BISAMIDINES THE GEORGIA STATE UNIVERSITY 2001-04-10 US disclosed
US-6025398-A Benzamidoxime prodrugs as antipneumocystic agents THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2000-02-15 US disclosed
US-5843980-A Benzamidoxime prodrugs as antipneumocystic agents GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 1998-12-01 US disclosed
EP-0861071-A1 BENZAMIDOXIME PRODRUGS AS ANTIPNEUMOCYSTIC AGENTS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1998-09-02 EP disclosed
US-5723495-A TREATMENT OF PNEUMONIA THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1998-03-03 US disclosed
WO-1997017949-A1 BENZAMIDOXIME PRODRUGS AS ANTIPNEUMOCYSTIC AGENTS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1997-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044468-A1 Benzamidoxime prodrugs as antipneumocystic agents BHMT, BBOX1, BCHE MMP1 225/4885CYP1A2 597/4885KDM4E 2197/4885
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 MMP1 281/4885CYP1A2 820/4885KDM4E 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.